Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6646
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators:
- 18 May 2026 - 16 June 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 May 2026 | In progress. Scoping commenced. |
| 09 October 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual